Boehringer Ingelheim and Eli Lilly’s Empagliflozin (Jardiance) Granted New Indication in China for Reducing Cardiovascular Mortality in Adults with Type 2 Diabetes and Cardiovascular Disease

On May 30, the official website of the National Medical Products Administration (NMPA) showed that the new indication application for Jardiance (generic name: empagliflozin tablets), a sodium-glucose co-transporter 2 (SGLT2) inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly, was approved. The speculated indication is to reduce the risk of cardiovascular death in patients with type 2 diabetes and cardiovascular disease.

In August 2017, empagliflozin was approved for the first time in China for the treatment of type 2 diabetes. In June 2022, a new indication for empagliflozin was approved in China for the treatment of adult patients with heart failure with reduced ejection fraction, with or without diabetes. In August 2022, the third indication for empagliflozin was approved in China for the treatment of adult patients with heart failure with preserved ejection fraction.

Empagliflozin was first approved by the FDA for marketing in August 2014 for the treatment of type 2 diabetes. To date, empagliflozin has secured four indications: heart failure with preserved ejection fraction, type 2 diabetes, heart failure with reduced ejection fraction, and cardiovascular risk. Since its launch, the sales of empagliflozin have been on a steady rise, reaching $8.215 billion globally in 2022.

Copyright © 2023 PHARMCUBE. All Rights Reserved.

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article; if you need to reproduce it, please leave a message to the WeChat Official Account or send a message, specifying the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

PharmaCube Reader Survey Questionnaire

Thank You for Your Company, Looking Forward to Your Feedback

Scan the QR code to provide valuable suggestions